Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

被引：0
|
作者：
McKean, M. [1 ]
Barve, M. [2 ]
Hong, D. [3 ]
Parikh, A. [4 ]
Rosen, E. [5 ]
Yang, J. [6 ]
Picard, R. [6 ]
Yi, J. [6 ]
Brail, L. [6 ]
Vecchio, D. [6 ]
Meniawy, T. [7 ]
John, T. [8 ]
Wang, J. [9 ]
机构：
[1] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[2] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[3] MD Anderson, Invest Canc Therapeut ICT, Houston, TX USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[6] Erasca Inc, San Diego, CA USA
[7] Linear Clin Res & Univ Western Australia, Med Oncol, Nedlands, WA, Australia
[8] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[9] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
95
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [41] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Alex A. Adjei
    Patricia LoRusso
    Antoni Ribas
    Jeffrey A. Sosman
    Anna Pavlick
    Grace K. Dy
    Xiaofei Zhou
    Esha Gangolli
    Michelle Kneissl
    Stephanie Faucette
    Rachel Neuwirth
    Viviana Bózon
    Investigational New Drugs, 2017, 35 : 47 - 58
  • [42] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    A. Hollebecque
    E. Deutsch
    C. Massard
    C. Gomez-Roca
    R. Bahleda
    V. Ribrag
    C. Bourgier
    V. Lazar
    L. Lacroix
    A. Gazzah
    A. Varga
    T. de Baere
    F. Beier
    S. Kroesser
    K. Trang
    F. T. Zenke
    M. Klevesath
    Jean-Charles Soria
    Investigational New Drugs, 2013, 31 : 1530 - 1538
  • [43] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
    Li, Huiping
    Liu, Rongrui
    Shao, Bin
    Ran, Ran
    Song, Guohong
    Wang, Ke
    Shi, Yehui
    Liu, Jihong
    Hu, Wenjing
    Chen, Fu
    Liu, Xiaoran
    Zhang, Gairong
    Zhao, Chuanhua
    Jia, Ru
    Wang, Quanren
    Rugo, Hope S.
    Zhang, Yifan
    Li, Guangze
    Xu, Jianming
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +
  • [44] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Yongkun Sun
    Lin Yang
    Xuezhi Hao
    Yutao Liu
    Jinwen Zhang
    Zhiqiang Ning
    Yuankai Shi
    Journal of Hematology & Oncology, 12
  • [45] Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors
    Kaneda, H.
    Okamoto, I.
    Satoh, T.
    Arao, T.
    Nishio, K.
    Sarashina, A.
    Konishi, K.
    Stopfer, P.
    Kaiser, R.
    Nakagawa, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 133 - 133
  • [46] A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.
    Lickliter, Jason D.
    Gan, Hui Kong
    Meniawy, Tarek
    Yang, Jason
    Wang, Lai
    Luo, Lusong
    Lu, Ni
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.
    Rosen, L. S.
    Wilding, G.
    Sweeney, C.
    Casale, D.
    Kollia, G.
    Wu, C.
    Ayers, M.
    Hill, C.
    Galbraith, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 133S - 133S
  • [48] A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation
    Heumann, Thatcher Ross
    Stockton, Shannon
    Cecchini, Michael
    Aljumaily, Raid
    Shyr, Cathy
    Whisenant, Jennifer
    Starr, Jason S.
    Dayyani, Farshid
    Baranda, Joaquina Celebre
    Trikalinos, Nikolaos
    Ivy, S. Percy
    LoRusso, Patricia
    Das, Satya
    Gore, Steven
    Beumer, Jan Hendrik
    Berlin, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.
    Johnson, Melissa Lynne
    Burns, Timothy F.
    Thompson, Jonathan Robert
    Spira, Alexander I.
    Alexander, Mariam
    Blumenschein, George R.
    Michalski, Joel
    Bilic, Sanela
    Teh, Aza
    Lai, Katharine C.
    McGann, Shane
    Chalk, Helen
    Haystrand, Lisa
    Wu, Ting-Hui
    Gallant, Gilles
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors
    Rosen, L.
    Garcia, A.
    Mulay, M.
    Cunningham, C.
    Nemunaitis, J.
    Senzer, N.
    Li, C.
    Dovholuk, A.
    O'Keefe, S.
    Bukowksi, R.
    Mekhail, T.
    EJC SUPPLEMENTS, 2006, 4 (12): : 196 - 196
12345